Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease

Jeanne Palmer, Xiaoyu Chai, Paul J. Martin, Daniel Weisdorf, Yoshihiro Inamoto, Joseph Pidala, Madan Jagasia, Steven Pavletic, Corey Cutler, Georgia Vogelsang, Sally Arai, Mary E.D. Flowers, Stephanie J. Lee

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Failure-free survival, defined as the absence of relapse, non-relapse mortality or addition of another systemic therapy, has been proposed as a potential endpoint for clinical trials, but its use has only been reported for single-center studies. We measured failure-free survival in a prospective observational cohort of patients (n=575) with both newly diagnosed and existing chronic graft-versus-host disease from nine centers. Failure was observed in 389 (68%) patients during the observation period. The median follow up of all patients was 30.9 months, and the median failure-free survival was 9.8 months (63% at 6 months, 45% at 1 year, and 29% at 2 years). Of the variables measured at enrollment, ten were associated with shorter failure-free survival: higher National Institutes of Health 0-3 skin score, higher National Institutes of Health 0-3 gastrointestinal score, worse range of motion summary score, lower forced vital capacity (%), bronchiolitis obliterans syndrome, worse quality of life, moderate to severe hepatic dysfunction, absence of treatment for gastric acid, female donor for male recipient, and prior grade II-IV acute graft-versus-host disease. Addition of a new systemic treatment, the major cause of failure, was associated with an increased risk of subsequent non-relapse mortality (hazard ratio=2.06, 95% confidence interval: 1.29- 3.32; P<0.003) and decreased survival (hazard ratio=1.51, 95% confidence interval: 1.04-2.18; P<0.03). These results show that fewer than half of patients on systemic treatment will be failure-free survivors at 1 year, and fewer than a third will reach 2 years without experiencing failure. Better treatments are needed for chronic graftversus- host disease. identifier: NCT00637689.

Original languageEnglish (US)
Pages (from-to)690-695
Number of pages6
Issue number5
StatePublished - 2015

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease'. Together they form a unique fingerprint.

Cite this